MX2021010739A - Celulas madre mesenquimales inmunomoduladoras. - Google Patents

Celulas madre mesenquimales inmunomoduladoras.

Info

Publication number
MX2021010739A
MX2021010739A MX2021010739A MX2021010739A MX2021010739A MX 2021010739 A MX2021010739 A MX 2021010739A MX 2021010739 A MX2021010739 A MX 2021010739A MX 2021010739 A MX2021010739 A MX 2021010739A MX 2021010739 A MX2021010739 A MX 2021010739A
Authority
MX
Mexico
Prior art keywords
mesenchymal stem
cell
immunomodulating
stem cells
current invention
Prior art date
Application number
MX2021010739A
Other languages
English (en)
Spanish (es)
Inventor
Jan Spaas
Sarah Broeckx
Original Assignee
Boehringer Ingelheim Veterinary Medicine Belgium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Veterinary Medicine Belgium filed Critical Boehringer Ingelheim Veterinary Medicine Belgium
Publication of MX2021010739A publication Critical patent/MX2021010739A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/03—Compounds acting on the NO pathway, e.g. nitrososarginine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021010739A 2019-03-12 2020-03-12 Celulas madre mesenquimales inmunomoduladoras. MX2021010739A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19162270 2019-03-12
PCT/EP2020/056625 WO2020182935A1 (en) 2019-03-12 2020-03-12 Immunomodulating mesenchymal stem cells

Publications (1)

Publication Number Publication Date
MX2021010739A true MX2021010739A (es) 2021-12-15

Family

ID=65801891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010739A MX2021010739A (es) 2019-03-12 2020-03-12 Celulas madre mesenquimales inmunomoduladoras.

Country Status (10)

Country Link
US (1) US20220154147A1 (US06244707-20010612-C00007.png)
EP (1) EP3938494A1 (US06244707-20010612-C00007.png)
JP (1) JP2022524764A (US06244707-20010612-C00007.png)
KR (1) KR20210139259A (US06244707-20010612-C00007.png)
CN (1) CN113677789A (US06244707-20010612-C00007.png)
AU (1) AU2020235912A1 (US06244707-20010612-C00007.png)
BR (1) BR112021017738A8 (US06244707-20010612-C00007.png)
CA (1) CA3132414A1 (US06244707-20010612-C00007.png)
MX (1) MX2021010739A (US06244707-20010612-C00007.png)
WO (1) WO2020182935A1 (US06244707-20010612-C00007.png)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117835995A (zh) 2021-07-08 2024-04-05 勃林格殷格翰比利时兽医公司 用于治疗慢性龈口炎的间充质干细胞
KR20240034745A (ko) 2021-07-08 2024-03-14 베링거 인겔하임 베터리너리 메디슨 벨기에 동물의 골관절염 치료용 중간엽 줄기세포
CN117915924A (zh) 2021-07-08 2024-04-19 勃林格殷格翰比利时兽医公司 间充质干细胞用于治疗慢性肾病
EP4366748A1 (en) 2021-07-08 2024-05-15 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of atopic dermatitis
WO2024033462A1 (en) 2022-08-11 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines
WO2024133886A1 (en) * 2022-12-23 2024-06-27 Boehringer Ingelheim Veterinary Medicine Belgium Primed mesenchymal stem cells for use in the treatment of chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU755888B2 (en) 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
WO2012051210A2 (en) * 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
AU2017235446A1 (en) 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy

Also Published As

Publication number Publication date
CN113677789A (zh) 2021-11-19
KR20210139259A (ko) 2021-11-22
EP3938494A1 (en) 2022-01-19
BR112021017738A8 (pt) 2022-08-02
JP2022524764A (ja) 2022-05-10
AU2020235912A1 (en) 2021-10-07
BR112021017738A2 (US06244707-20010612-C00007.png) 2021-11-16
US20220154147A1 (en) 2022-05-19
CA3132414A1 (en) 2020-09-17
WO2020182935A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
MX2021010739A (es) Celulas madre mesenquimales inmunomoduladoras.
SA519401455B1 (ar) طريقة لعزل الخلايا الجذعية اللحمية المتوسطية من الغشاء السلوي للحبل السري باستخدام مستنبت خلايا متوسطية
WO2018097540A3 (ko) 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물
MX2019005476A (es) Ensayo de celulas madre pluripotentes.
DK1261694T3 (da) Pluripotente stamceller som er genereret ud fra stromaceller der er afledt af adipöst væv samt anvendelser deraf
EP3947642A4 (en) CULTURE MEDIUM FOR MAMMALIAN PLURIPOTENTE STEM CELLS, COMPOSITION AND METHODS
MX2018001531A (es) Medio de cultivo celular complementado con taurina y metodos de uso.
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
WO2018185709A9 (en) Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
PH12014501175B1 (en) Medium composition for rejuvenating stem cells
CA2886946C (en) Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour
EP1904624A4 (en) METHOD FOR THE CULTIVATION AND REPRODUCTION OF HEMATOPOETIC STEM CELLS AND PRECURSOR CELLS USING HUMAN ENDOMETRIUM CELLS
EP3737742A4 (en) EFFICIENT DERIVATION OF STABLE PLURIPOTENT EMBRYONAL BOVINE STEM CELLS
MX2021012041A (es) Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas.
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
MX2021011622A (es) Células t específicas de antígeno de multiples virus respiratorios y métodos para elaborar y usar las mismas de manera terapéutica.
RU2015139970A (ru) Популяция стволовых клеток шейки матки человека и ее применение
EP4029566A4 (en) SERUM-FREE MEDIUM NOT CONTAINING ALBUMINE SUITABLE FOR CULTIVATION OF HUMAN HEMATOPOIETIC STEM CELLS AND ALBUMIN-FREE CULTIVATION METHOD
EP3893868A4 (en) COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS T-CELL LYMPHOMA (CTCL)
MX2023011927A (es) Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
EP3892719A4 (en) UNDIFFERENTIATED STATE-MAINTAINING CULTURE MEDIUM FOR PLURIPOTENTIC STEM CELLS
EP3902909A4 (en) METHODS OF REGULATION OF POTENCY OF PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF
MX2020008897A (es) Expansion y diferenciacion de citoblastos.
AR112303A1 (es) Método para el tratamiento de un efecto secundario de la inmunoterapia